Maze Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	20	-	167.5	-	-
Revenue Growth (YoY)	-88.06%	-	-	-	-
Gross Profit	20	-	167.5	-	-
Selling, General & Admin	39.04	34.45	26.42	24.61	22.83
Research & Development	115.02	108.45	83.5	73.95	88.19
Total Operating Expenses	154.05	142.9	109.91	98.55	111.03
Operating Income	-134.05	-142.9	57.59	-98.55	-111.03
Interest Income	12.38	11.78	4.65	1.97	2.03
Interest Expense	-0.87	-	-	-	-
Other Non-Operating Income (Expense)	-	-	-8.84	-3.83	-5.94
Total Non-Operating Income (Expense)	11.51	11.78	-4.18	-1.86	-3.91
Pretax Income	-98.33	-131.12	53.4	-100.42	-114.94
Provision for Income Taxes	-	-	1.17	-	-
Net Income	-34.57	-131.12	3.41	-100.42	-114.94
Net Income to Common	-34.57	-131.12	3.41	-100.42	-114.94
Shares Outstanding (Basic)	49	43	2	2	2
Shares Outstanding (Diluted)	49	43	3	2	2
Shares Change (YoY)	420.95%	1474.04%	19.33%	13.88%	-
EPS (Basic)	-2.53	-3.05	1.42	-43.89	-57.21
EPS (Diluted)	-2.53	-3.05	1.25	-43.89	-57.21
Shares Outstanding	49.74	49.34	2.45	2.39	2.37
Free Cash Flow	-121.86	-112.73	74.81	-87.27	-101.17
Free Cash Flow Per Share	-2.48	-2.62	27.40	-38.14	-50.36
Gross Margin	100.00%	-	100.00%	-	-
Operating Margin	-670.25%	-	34.38%	-	-
Profit Margin	-444.31%	-	31.18%	-	-
FCF Margin	-609.29%	-	44.66%	-	-
EBITDA	-131.89	-140.5	60.88	-94.46	-107.21
EBITDA Margin	-659.44%	-	36.35%	-	-
EBIT	-134.05	-142.9	57.59	-98.55	-111.03
EBIT Margin	-670.25%	-	34.38%	-	-
Effective Tax Rate	-	0.00%	2.19%	0.00%	0.00%

SEC Filings: 10-K · 10-Q